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Abstract Recent developments in spatial proteomics have
paved the way for retrospective in situ mass spectrometry
(MS) analyses of formalin-fixed paraffin-embedded clinical
tissue samples. This type of analysis is commonly referred to
as matrix-assisted laser desorption/ionization (MALDI) imag-
ing. Recently, formalin-fixed paraffin-embedded MALDI im-
aging analyses were augmented to allow in situ analyses of
tissue-specific N-glycosylation profiles. In the present study,
we outline an improved automated sample preparation meth-
od for N-glycan MALDI imaging, which uses in situ PNGase
F-mediated release and measurement of N-linked glycans
from sections of formalin-fixed murine kidney. The sum of
the presented data indicated that N-glycans can be cleaved
from proteins within formalin-fixed tissue and characterized
using three strategies: (i) extraction and composition analysis
through on-target MALDI MS and liquid chromatography
coupled to electrospray ionization ion trap MS; (ii) MALDI
profiling, where N-glycans are released and measured from
large droplet arrays in situ; and (iii) MALDI imaging, which
maps the tissue specificity of N-glycans at a higher resolution.
Thus, we present a complete, straightforward method that
combines MALDI imaging and characterization of tissue-
specific N-glycans and complements existing strategies.
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Introduction
The majority of mammalian secretory and membrane proteins
are modified through glycosylation: the covalent linkage of
polysaccharide moieties (i.e., glycans) to either serine/
threonine (O-linked) or asparagine (N-linked) residues [1].
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As such, glycosylation is one of the most common posttrans-
lational modifications (PTM) [1, 2]. Global analysis of gly-
cans and glycoproteins is currently pursued through
glycomics and glycoproteomics, respectively [3]. Glycomics
focuses on the isolation and characterization of glycans [3],
while glycoproteomics focuses on the elucidation of informa-
tion such as the identity of glycosylated proteins, glycan
composition, glycosylation site, and the role of the glycopro-
tein in cellular function and/or dysfunction [1]. Much of the
interest in the analysis of protein glycosylation stems from the
observation of altered glycosylation patterns in cancer [1]. An
understanding of these alterations could provide novel bio-
markers of disease as well as new treatment targets for anti-
cancer therapies [4].
There are currently a limited number of mass spectrom-
etry (MS)-based methods available for interrogating clin-
ical tissue samples for variations in glycosylation patterns.
One reason for this has been the perception that the most
common type of archival clinical sample, formalin-fixed
paraffin-embedded (FFPE) tissue, was difficult to access
for glycoproteomic and proteomic analyses. However, re-
cent work has demonstrated that the inter- and intraprotein
cross-links induced by formalin do not preclude the anal-
ysis of FFPE tissue proteomes by bottom-up liquid chro-
matography (LC)-MS/MS-based proteomics [5] and that
N-glycosylation sites cannot only be mapped but are quan-
titatively conserved during the fixation process [6, 7]. The
ability to analyze the glycoproteome of FFPE tissues will
allow for retrospective analysis of the substantial clinical
tissue archives which exist worldwide [8]. Such an ap-
proach would represent a significant step forward for
glycoproteomic cancer research. Unfortunately, quantita-
tive glycoproteomics methods are typically time-consum-
ing, require extensive sample preparation procedures, and
sacrifice spatial proteome information when the tissue is
solubilized. Direct tissue analysis by MS, otherwise
known as matrix-assisted laser desorption/ionization
(MALDI) imaging, provides a unique solution to these
issues [9]. MALDI imaging allows for the rapid collection
of molecular information directly from tissue sections,
without the need for homogenization, fractionation, or
application of antibody-based techniques. [10, 11] Fur-
thermore, because the MS data is spatially referenced, it
can be overlaid directly with histology and tissue sections
can be annotated with the spatial distribution of biological
analytes [12, 13].
As mentioned above, until relatively recently, FFPE tissues
were not regularly analyzed by MALDI imaging. Seminal
work by Groseclose et al. in 2008 adapted the bottom-up
approach for the analysis of FFPE tissues by combining
antigen retrieval with spatially sensitive tryptic digestion for
MALDI imaging. This approach was used to successfully
classify subtypes of human lung tumor [14]. Combined with
the observation that N-glycosylation can be analyzed in FFPE
tissues, this work paved the way for glycan MALDI imaging.
Powers et al. showed that N-glycan MALDI imaging is
achievable on sections of native tissue [15]. Furthermore,
Yamada et al. demonstrated access to oligosaccharides by α-
amylase digestion of FFPE human intestinal tissue containing
an amylopectin-rich obstruction [16]. Finally, during the prep-
aration of this manuscript, Toghi Eshghi et al. and Powers
et al. demonstrated the application of N-glycan MALDI im-
aging to FFPE murine brain tissue [17], murine kidney, glio-
mas, and tissue microarrays [18].
Herein, we present a complementary three-component au-
tomated sample preparation and characterization strategy de-
veloped for N-glycans released in an FFPE murine kidney
model. The first component of this strategy was a low spatial
resolution in situ MALDI profiling method for the measure-
ment of N-glycans directly from specific tissue types. To
confirm the detection of N-glycans, the second component
used in-solution enzymatic release of N-glycans from FFPE
kidney tissue followed by characterization using MALDI-
time of flight (TOF)/TOF MS and LC-electrospray ionization
(ESI)-IT MS/MS. The third and final components employed a
higher spatial resolution MALDI imaging method to compre-
hensively map the tissue-specific distributions of the charac-
terized N-glycans.
The presented work is complementary to existing methods
and takes the next step in combining N-glycan MALDI imag-
ing in kidney tissue with glycomic characterization by MS/
MS. This method can potentially be used for interrogation of




Glycerol-free PNGase F (P0705L, 75,000 NEB units) was
purchased from New England Biolabs (Ipswich, MA, USA).
2,5-DHB matrix was purchased from Sigma-Aldrich
(Steinheim, Germany) and Bruker Daltonics (Bremen, Ger-
many). Formalin was from Sigma-Aldrich. Trifluoroacetic
acid (TFA), ethanol, and NaCl were from Merck (Darmstadt,
Germany). Nitrocellulose membranes (0.025 μm VSWP) for
dialysis were purchased from Millipore (Cork, Ireland). Xy-
lene was purchased from Chem-Supply (Gillman, South Aus-
tralia). Indium tin oxide (ITO) slides were purchased from
Bruker Daltonics, while PEN membrane slides were from
MicroDissect (Herborn, Germany). GLY3 standards (see Ta-
ble 1) were purchased from Prozyme (CA, USA). Unless
otherwise stated, all H2O used was ultrapure (i.e., ≥18.2 MΩ
and ≤5 ppb TOC).
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Tissue sectioning
Murine kidney tissue was scavenged from mice sacrificed as
part of experiments with full ethics approval and in accor-
dance with the policies of the University of Adelaide Ethics
Committee. Formalin was diluted 1:9.25 in 1× PBS, and
tissues were immersed in this solution overnight at 4 °C.
The tissue was then removed from the formalin, rinsed with
deionized H2O, and stored in 70 % ethanol (EtOH) before
processing with a Leica TP 1020 processor (Leica
Biosystems, North Ryde, Australia). The protocol was as
follows: 70 % EtOH for 5 min, 80 % EtOH for 2 h, 95 %
EtOH for 2 h, 3× 100 % EtOH for 2 h each, 2× xylene for 2 h
each, and 2× paraffin for 2 h each. A Leica EG 114OH
embedder (Leica Biosystems) was used to create paraffin-
embedded tissue blocks. FFPE blocks were sectioned (6 μm
thick) on a Microm HM 325 microtome (Zeiss, Göttingen,
Germany) and water bath mounted (39 °C) onto ITO slides
(Bruker Daltonics) or PEN membrane slides (MicroDissect).
Slides were left to dry at 37 °C for 1 h prior to storage at 4 °C.
In-solution PNGase F digestion and matrix preparation
and MALDI-TOF/TOF MS
Tissue on PEN membrane slides (n=3) was used for manual
microdissection and processing as described previously [19,
20], with modifications. Briefly, following a 5 min 60 °C
heating block incubation, 90 s xylene wash, and 60 s EtOH
wash, the kidney tissue sections were isolated by manual
microdissection and deposited into separate microvials. The
tissue was incubated (2×5 min) in 10 mMNH4HCO3, and the
solution was removed and replaced with 10 mM citric acid
(pH 6) and heated at 98 °C for 45 min. The tissue was washed
twice with 10mMNH4HCO3. Glycerol-free PNGase F (2 μL,
nondialyzed) was added to the FFPE tissue in a 40 μL total
reaction volume (with 25 mM NH4HCO3). The tissue digest
was left overnight at 37 °C. The reaction volume was then
spotted (1 μL) onto an MTP-384 800 μm AnchorChip
target (Bruker Daltonics) and allowed to dry at room temper-
ature. A custom N-glycan standard (GLY3 standard, see Ta-
ble 1) was spotted (0.5 μL) onto calibrant AnchorChip spots.
The sample was overlaid using a modified EZYprep depo-
sition method [21]. Briefly, 10mg/mL 2,5-DHB in 0.1 % TFA
and 1 mM NaCl was deposited in multiple layers using
custom settings [0.075 mL/min flow rate, 4 psi N2 pressure,
85 °C capillary temperature, 8 passes, 800 mm/min] for a TM
sprayer instrument (HTX Technologies, Carrboro, NC, USA).
MS data was acquired on an ultrafleXtreme MALDI-TOF/
TOF instrument operated through an autoXecute method in
flexControl (v3.4, Bruker Daltonics). External calibration was
performed using the GLY3 standard (Table 1). MS spectra
were processed in flexAnalysis. Peaks were picked using the
SNAP algorithm with an averagine approximation and signal
to noise (S/N) >3.
N-glycan purification and LC-ESI-ion trap MS and MS/MS
The released N-linked glycans were reduced and desalted
according to previously described methods [22]. After acidi-
fication with 100 mMNH4COOH pH 5 (10 μL) for 60 min at
room temperature, the samples were dried in a vacuum cen-
trifuge and were reduced with 20 μL of 1MNaBH4 in 50mM
KOH at 50 °C for 3 h. The reduction was quenched with 1 μL
glacial acetic acid, and the N-linked glycan alditols were
desalted as described below. The released glycans were
desalted using cation-exchange columns comprising 30 μL
AG50W-X8 cation-exchange resin (Bio-Rad, Hercules)
packed on top of a C18 StageTip Frit. Residual borate was
removed by the addition of methanol (3×) and dried under
vacuum. The glycans were further purified by tips using
porous graphitized carbon slurry manually packed onto C18
StageTip Frits as previously described [22]. The glycans were
resuspended in 10 μL of Milli-Q water and subjected to
porous graphitized carbon (PGC)-LC-ESI MS/MS separation
and analysis. N-linked glycan alditols were separated using an
Agilent 1100 capillary LC (Agilent Technologies, Santa Clara,
CA) and analyzed using an Agilent MSD, three-dimensional
ion trap XCT mass spectrometer coupled to the LC. Separa-
tion was performed on a Hypercarb PGC column (3 μm
particle size, 100×0.18 mm, Hypercarb, Thermo Scientific)
across an 85 min gradient with a constant flow rate of 2 μL/
min using a linear gradient up to 45% (v/v) CH3CN in 10 mM
NH4HCO3. ESIMSwas performed in negative ion mode with
two scan events: MS full scan with mass range 100–2000 m/z
and data-dependent MS/MS scan after collision-induced dis-
sociation (CID) of the top two most intense precursor ions.
PNGase F dialysis and tissue section antigen retrieval
Neat PNGase F enzyme (20 μL for profiling, 40 μL for
MALDI imaging) was dialyzed on a nitrocellulose membrane
against water for 2 h. Tissue sections were rehydrated using a
Table 1 N-glycan standard mix-
ture (GLY3) used for calibration
of MALDI-TOF/TOF MS
instrument
N-glycan composition [M] [M+Na]+ Concentration Company
Man5GlcNAc2 1234.4333 1257.4225 1 pmol/μL Prozyme, CA, USA
Man3GlcNAc5 1519.5659 1542.5551
Man3Gal4GlcNAc6 2370.8565 2393.8457
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standard procedure for citric acid antigen retrieval (CAAR)
[20]. Briefly, the tissue sections were heated at 60 °C for 1 h
and washed in 100 % xylene (2×5 min) and 100 % ethanol
(2×2 min). Sections were washed in 10 mM NH4HCO3 (2×
5 min) followed by a 10 min pulse boil in 10 mM citric acid
(pH 6.0) followed by heating at 98 °C for 30 min on a heating
block. Finally, the tissue sections were immersed twice in
10 mM NH4HCO3 (1 min) and dried at room temperature in
a humid chamber.
In situ PNGase F digestion and matrix deposition
NH4HCO3 (25 mM, pH ∼8.2) was added to the dialyzed
PNGase F to a total volume of 100 μL for profiling or
200 μL for MALDI imaging. PNGase F was printed onto
retrieved tissue sections—750 nL at 1300 μm center to center
spacing for profiling or 30 nL at 250 μm spacing for MALDI
imaging—using a ChIP-1000 (Shimadzu, Japan). Buffer con-
trol arrays (25 mM NH4HCO3) were printed using the same
conditions on adjacent sections. Tissue sections were incubat-
ed overnight at 37 °C in a humid chamber, and GLY3 standard
was manually spotted (0.5 μL) on an adjacent section. 2,5-
DHB (10 mg/mL for profiling or 20 mg/mL for MALDI
imaging) in 0.1 % TFA and 1 mM NaCl was sprayed onto
prepared tissues using a TM sprayer. Instrument-specific set-
tings are as follows: 16 passes, 0.05 mL/min flow rate, 4 psi
N2 pressure, 65 °C capillary temperature, and 800 mm/min.
MALDI-TOF/TOF mass spectrometry and histological
staining
MS data was acquired using an ultrafleXtreme MALDI-TOF/
TOF mass spectrometer (Bruker Daltonics) controlled by
flexControl (v3.4, Bruker Daltonics) and flexImaging (v4.0,
Bruker Daltonics). Instrument-specific settings were as fol-
lows: 800–4500m/z range, 700 Da matrix suppression, 2 kHz
laser repetition rate, and 2.5 GS/s.
(i) Profiling:Method-specific settings were as follows: 70%
laser power and 2694 V detector gain. A total of 10,000
shots (random walk) were acquired at each treatment
position and the calibration spots for each of the four
profiling replicates.
(ii) Imaging:Method-specific settings were as follows: 75%
laser power and 2698 V detector gain. A total of 1000
shots were acquired at each position with no walk. Data
was acquired by oversampling from an arbitrary array
with center to center acquisition distance of 100 μm
overlaid onto the 250 μm PNGase F array. The
MALDI-TOF/TOF instrument was externally calibrated
using the included GLY3 standard spots prior to MALDI
imaging.
Following analysis, the matrix was eluted using 70 %
EtOH and tissue sections were hematoxylin and eosin (H &
E)-stained using a standard protocol.
Data analysis—MALDI profiling and MALDI imaging
(i) Profiling: Baseline-subtracted MS spectra were visual-
ized in flexImaging (Bruker Daltonics) using data reduc-
tion to 20,000 points and root mean square (RMS) nor-
malization. External calibrant spectra were internally
recalibrated using a quadratic fit to the GLY3 mass con-
trol list in flexAnalysis (v3.4, Bruker Daltonics). Of two
calibrant spots, the best calibration was copied to all MS
spots (buffer control and PNGase F) for that respective
tissue section. Calibration was repeated for all sections
(N=4). All peak lists were exported using flexAnalysis
into ASCII text files. A custom R [23] script was written
to further process these peak lists. Text files were com-
bined and peaks were grouped using a linkage distance of
0.1m/z. Peak groups occurring in ≥2 counts in the
PNGase F spectra and ≤1 count in the buffer control
spectra were considered. Abundance weighted mean
(AWM, weighted by S/N) m/z was calculated for each
of these peak groups.
(ii) MALDI imaging: Data was analyzed by SCiLS Lab
(version 2014a, SCiLS GmbH, Bruker Daltonics) or by
exporting peak lists from flexAnalysis (TopHat baseline
subtraction and SN >3) and in-house R [23] processing
for difference in proportions statistic (DIPPS) analysis.
For the SCiLS analysis, raw data was loaded and re-
duced to 50,000 points per spectrum. Data was
preprocessed by baseline subtraction and normalization
to total ion current (TIC). Peaks were picked and aligned,
and the preprocessed data was used for spatial segmen-
tation (bisecting k-means with correlation distance) as
well as a random initialization probabilistic latent seman-
tic analysis (pLSA) with 10 components. Minimal inter-
val width was set to 0.5 Da for both analyses. For DIPPS
analysis in R, peaks were grouped using a linkage dis-
tance of 0.1 Da, and weighted mean m/z values were
calculated for each peak group using S/N ratios for
weights. Only peak groups (i.e., analytes) occurring in
at least 100 spectra were considered. The difference in
proportions of occurrence (between PNGase F-treated
and control regions), known as DIPPS statistics, was
calculated. A high DIPPS value (close to 1) for a given
peak group indicates that peaks in that peak group occur
in a high proportion of spectra from PNGase F-treated
regions and a low proportion of spectra from control
regions. DIPPS maps were created which show the
spatial distribution of a selected number of peak groups
(with high DIPPS) by counting the number of the select-
ed peak groups that exhibit peaks in each spectrum and
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plotting those counts spatially. The number of peak
groups selected for inclusion can be data independent
(i.e., user selected) or data dependent (i.e., based upon a
heuristic cut-off). Log ion intensity maps were also
created for peak groups with high DIPPS. The develop-
ment and use of the DIPPS method are further described
in an unpublished work [24].
Results and discussion
Formalin-fixed tissue sections are unique in that the proteome
is cross-linked extensively and is immobilized as a result. This
situation is advantageous for glycomic MALDI imaging be-
cause glycosidases can be applied directly to the tissue to
release N-glycans. These N-glycans can then be analyzed as
a relatively pure population without the presence of contam-
inating endogenous analytes such as lipids and peptides,
which would be present in native tissue sections. In order to
leverage this advantage and to address both of the typical in
situ MS measurement modes, the work presented in this
manuscript developed both large droplet profiling and spatial-
ly resolved MALDI imaging approaches for N-glycan
analysis.
To achieve profiling and demonstrate coarse tissue-specific
MS measurement of the observable N-glycan population in
FFPE tissue, four replicate FFPE murine kidney tissue sec-
tions were treated with antigen retrieval, and large droplets of
glycerol-free PNGase F were printed onto the sections and
incubated overnight at 37 °C. To minimize the amount of salt
deposited in situ and maximize signal quality, glycerol-free
PNGase F was dialyzed against ultrapure water prior to resus-
pension in NH4HCO3. Following incubation, the droplet ar-
rays were prepared with 2,5-DHB. Unfortunately, typical
dried droplet preparations with 2,5-DHB cause problems for
both manual and automated MS acquisitions: this is predom-
inantly due to the size and heterogeneity of the crystals (see
examples of crystal shape from previous experiments in the
Electronic Supplementary Material (ESM) Fig. S1a), which
leads to mass errors, “sweet spot” formation, and a concom-
itant decrease in signal reproducibility [21]. As a result, we
opted to avoid printing matrix onto the profiling spots and
instead adapted our previously published EZYprepmethod for
use on a TM sprayer instrument (HTX) [21]. EZYprep depo-
sitions involve nebulization of matrix onto pre-prepared sam-
ple, a process that produces finer 2,5-DHB crystals (see ESM
Fig. S1b), which in turn reduces sweet spot formation and
improves mass accuracy, reproducibility, and signal intensity.
As such, a TM sprayer was used to deposit multiple 2,5-DHB
layers, followed by MALDI-TOF/TOF MS. Figure 1a shows
a H & E stain for one of the four MALDI profiling sections,
with the major histological regions, cortex, medulla, and
pelvis annotated, and the border between the cortex and
medulla indicated with a red dotted line [25]. Figure 1b high-
lights the molecular profiling locations overlaid with the H &
E stain. These locations included four NH4HCO3 controls
(Fig. 1b, top), four PNGase F spots (Fig. 1b, middle), and
two N-glycan calibrant spots (see Table 1) (Fig. 1b, bottom).
The RMS normalized intensity form/z 2304.85 (AWMm/z) is
also presented in Fig. 1b. For this example m/z and multiple
others, the buffer control spots showed virtually no normal-
ized signal intensity. This was in contrast to the PNGase F
profiling spots which showed definitive signal and were able
to discern the first tissue-specific differences between the
cortex and medulla of the kidney section (see green ion
intensity in Fig. 1b).
Figure 1b clearly shows that the intensity differences across
the four PNGase F spots correspond to the internal structure of
the kidney. For example, m/z 2304.85 could be found in the
cortex but not in the medulla (green ion intensity signal in
Fig. 1b). The MS spectra for the tissue in Fig. 1a, b are
provided in Fig. 1c, d for the buffer control and PNGase F
profiling spots, respectively. MS spectra for the remaining
three replicate tissue sections are provided as ESM Fig. S2.
To isolate those peaks that occur predominantly in the
PNGase F profiling spots and, therefore, identify all the de-
tectable N-glycan candidates, externally calibrated peak lists
for all 32 spots (control and PNGase F) were grouped, and the
occurrence of all peak groups (i.e., analytes) in both control
and PNGase F spots was counted. In total, 79 peaks existed in
≥2 of the PNGase F spots and ≤1 of the buffer control spots
and were larger than m/z 1000. Making this threshold for N-
glycan candidate status more conservative (by requiring ≥4
counts in PNGase F spots) decreased the total to 43 N-glycan
candidates. As an example, m/z 2304.85 could be detected in
15/16 of the PNGase F-treated profiling locations and at a low
S/N in 1/16 buffer control locations. The few instances of
overlap in this manner were attributed to the possible delocal-
ization of PNGase F from an adjacent treated spot.
To confirm the identity of these candidates,N-glycans were
extracted directly from tissue sections for characterization.
This type of process is straightforward and allows the charac-
terization ofN-glycans from relatively small amounts of tissue
sample [26]. Sections of FFPE murine kidney tissue (N=3)
were manually microdissected, treated with antigen retrieval,
and incubated overnight with PNGase F (two of three sec-
tions). The experimental reaction supernatants, in addition to
the tissue only (one of three sections), PNGase F only, and
blank controls, were analyzed on an ultrafleXtreme MALDI-
TOF/TOF. The MS profiles for tissue only, PNGase F only,
and blank controls contained only a few peaks (see ESM
Fig. S3). In stark contrast, the MS spectra for both PNGase
F-tissue reaction supernatants contained multiple high S/N
peaks (see Fig. 2). Interestingly, when comparing the MS
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profiles for the in situ MALDI profiling and on-target
MALDI-TOF/TOF, an approximate 1 Da mass discrepancy
was noted for multiple N-glycans. Additionally, the isotopic
profiles of these N-glycans changed (see ESM Fig. S4). For
Fig. 1 In situ MS profiling of N-linked glycans released from formalin-
fixed murine kidney sections using dialyzed PNGase F. Four replicate
formalin-fixed murine kidney tissue sections were treated with antigen
retrieval followed by ChIP-1000 printing of PNGase F or buffer control.
An N-glycan calibrant mixture was spotted onto a separate part of the
section. Tissue was overlaid with 2,5-DHB in 0.1 % trifluoroacetic acid
and 1 mM NaCl using a TM sprayer instrument and MS spectra were
acquired using a MALDI-TOF/TOF. a Hematoxylin and eosin (H & E)-
stained murine kidney section annotated with the cortex, medulla, and
pelvic regions. Cortex-medulla interface marked by a red dotted line (see
Oetjen et al. [25]). b Overlay of H & E and profiling spots (blue dotted
outline) treated with PNGase F (middle), buffer control (top), and
calibrant spots (bottom). Ion intensity map in b is for mass filter
2304.778 (raw data loaded, baseline subtracted, data reduced to 20,000
points per spectrum, RMS normalization). The intensity map shows
definitive signal in PNGase F-treated spots, with tissue-specific differ-
ences clear between spots localized to the cortex and those in the medulla.
c, d The 4× control and 4× PNGase F MS spectra, respectively, for this
section. Spectra were exported (flexAnalysis) and formatted in MS
PowerPoint and InkScape (www.inkscape.org). MS spectra show clear
differences in peak number, with the PNGase F spots containing multiple
unique masses. Numbers with asterisks indicate N-glycan candidates
identified by LC-MS/MS—these are also annotated in Table 2
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example, the isotopic profile of [M+Na]+ on-target indicated
the overlap of two species at roughly 2303.8 and 2304.8. Two
possible explanations exist for this observation. Either there
are two differentN-glycan species with a difference in mass of
roughly 1 Da, or there are two forms of the same N-glycan. In
the latter case, the same N-glycan would exist with a
glycosylamine (e.g., 2303.8) or free reducing end (e.g.,
2304.8) at the HexNAc C1 position.
To further characterize the N-glycan mixture, the reaction
supernatant was reduced, desalted, and purified on in-house
packed carbon columns prior to graphitic column chromatog-
raphy coupled online to an ESI-ion trap. MS/MS resulted in
the identification of 34N-glycan peaks. Figure 3 shows an ion
chromatogram annotated with the structure proposals for N-
glycans identified by MS/MS. As can be seen, the structure
proposals include a mixture of oligo-mannose, complex and
hybrid N-glycans (example MS/MS spectra available as ESM
Fig. S5). All of the measured ions were doubly negatively
charged, with the exception of [M−H]−: 1235.5. Several acidic
N-glycans with terminal N-glycolylneuraminic acid and N-
Fig. 2 MALDI-TOF/TOF MS
and MS/MS of N-glycans re-
leased in-solution from formalin-
fixed murine kidney sections. MS
profile obtained from N-glycans
enzymatically released (PNGase
F) in-solution from FFPE kidney
tissue treated with antigen re-
trieval. Spectrum was acquired on
a MALDI-TOF/TOF MS instru-
ment in reflectron positive ion
mode and peaks were picked (no
further processing). Formatting in
MS PowerPoint and InkScape
(www.inkscape.org). Multiple
unique masses can be visualized
in the PNGase F-treated tissue
supernatant. (see corresponding
m/z of potential N-linked glycans
in Table 2)
Fig. 3 Ion chromatogram
annotated with structure
proposals forN-glycans identified
by ESI-ion trap MS/MS. N-gly-
cans released in-solution from
formalin-fixed murine kidney tis-
sue using PNGase F were re-
duced, desalted, and purified on a
carbon column prior to porous
graphitic column chromatography
coupled online to an ESI-ion trap
(IT) system. MS scan above is
annotated with the structure pro-
posals that resulted from MS/MS
structure profiling of the eluate
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acetylneuraminic acid were also identified during this anal-
ysis. The heat-induced antigen retrieval was used to ensure
that the sample preparation conditions for the extracted N-
glycans matched the in situ MALDI profiling. However,
the heating step was also expected to reduce the likelihood
of observing sialylated N-glycans. As such, it cannot be
ruled out that milder rehydration conditions could allow
the detection of more sialylated N-glycan species by LC-
MS/MS, and method modifications to achieve this warrant
further investigation.
Table 2 provides a combined list of theN-glycan candidates
which were found by MALDI profiling and further identified
and characterized byLC-MS/MS (Fig. 3). Included in the table
are the buffer control and PNGase F counts, the AWM [M+
Na]+ for eachN-glycan, its calculated [M+Na]+, the associated
error as well as the calculated and measured [M−2H]2− for the
Table 2 N-glycan candidates detected by large droplet profiling and
characterized by LC-ESI-ion trap MS/MS. Provided in this table are the
occurrence counts for N-glycan candidates found in formalin-fixed mu-
rine kidney by in situ profiling (buffer control + PNGase F spots), their
sodiated abundance weighted mean mass (profiling AWM [M+Na]+), the
calculated sodiated mass ([M+Na+]+ calculated), error (ppm) between the
profiling and calculated sodiatedmasses, the calculated doubly negatively
charged mass ([M−2H]2− calculated), the measured doubly negatively
charged mass ([M−2H]2− measured), proposed composition, the pro-
posed structure, and the calculated sodiated mass from a previous publi-
cation [27]
The column with the heading “*” indicates those N-glycans annotated in Fig. 1 MS spectra
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LC-MS/MS analysis. The proposed compositions and struc-
tures are also provided as well as the calculated [M+Na]+ from
a previous study, if available [27].
Mass correlations to the N-glycans in [27] are provided in
ESM Table S1. The full list of N-glycan candidates as well as
the N-glycans identified by LC-MS/MS is provided in ESM
Table S2. In total, 23 [M+Na]+ values from the profiling
analysis could be correlated to the calculated [M+Na]+ values
reported in [27]: this amounts to 67 % of the previously
reported glycan species. Identity could be assigned to 18 N-
glycan candidates in this study (Table 2). It should be noted
that several of the N-glycans not detectable during MALDI
profiling were acidic or high-mannose type (see Fig. 3). As
such, additional method developments to allow the detection
of these N-glycans by MALDI profiling would be beneficial
(e.g., derivatization), particularly for application to tumor
tissues where acidic N-glycans are known to be significantly
overrepresented.
To increase the spatial resolution of analysis, the profiling
method was miniaturized to allow for MALDI imaging on the
FFPE kidney tissue. Printing of PNGase F onto antigen-
retrieved tissue followed by overnight incubation at 37 °C
and spray deposition of 2,5-DHB was found to provide con-
sistent N-glycan signal across entire tissue sections. This
method was similar to that previously published by Toghi
Eshghi et al. [17], with the exception that the current method
is completely automated, uses contactless printing (i.e., does
not touch the tissue surface) of reagents, and employs sub-
stantially reduced buffer salt concentration (25 mM versus
1 M) for PNGase F digestion. In general, the most important
sample preparation requirements seemed to be the PNGase F
buffer pH and the homogeneity of the final deposited matrix
layer, which is ultimately affected by reproducibility of the
sample preparation method and the presence of contaminants
such as salts and polymers.
Duplicate FFPE kidney sections were prepared for N-gly-
can MALDI imaging. MS data was acquired by oversampling
printed PNGase F arrays. Figure 4a–c shows the H & E stains
for the duplicate PNGase F-treated sections and the buffer
control-treated section, respectively (measurement regions in-
dicated by a dashed white outline). A twofold approach was
taken to evaluate the acquired data in terms of (1) finding
masses unique to PNGase F-treated regions (as compared to
buffer control) and (2) the ability of the MALDI imaging data
to map histological regions of the kidney.
To address the unique masses in PNGase F-treated regions,
DIPPS were calculated. High values of DIPPS highlight
masses which show a high proportion of occurrence in the
PNGase F-treated region and a lower proportion of occurrence
in control, which would be expected to be N-glycans. Using a
data-dependent heuristic cut-off for the DIPPS value, 13 m/z
values were identified as optimal for characterizing the
PNGase F-treated tissues. Figure 4d–f contains the DIPPS
map representation of these 13m/z values for the two PNGase
F-treated tissue sections and buffer control section, respective-
ly. These DIPPS maps count the occurrence of the 13 selected
peak groups at each spatial location in the MALDI imaging
data set. The DIPPS maps for the duplicate sections indicated
that the majority of masses seem to be cortex specific, as this
region represents the majority of the tissue. The DIPPS map
for the buffer control-treated tissue (Fig. 4f) shows almost no
occurrence of these peak groups. Of the 13 values isolated by
DIPPS, nine values matched to those identified by LC-MS/
MS in Table 2. The AWMm/z values for these nineN-glycans
were 1257.473, 1905.697, 1743.643, 1581.587, 1850.730,
2304.909, 2158.844, 1419.532, and 1809.69. If, rather than
considering the top 13, we consider the top 26 peak groups as
ranked by DIPPS, the number of matches to LC-MS/MS
identified N-glycans increases to 16 (additional m/z values—
1663.632, 2816.115, 1485.591, 1688.663, 2012.773,
1647.635, and 2067.747—see Table 2).
Comparing the initial nine m/z values to their calculated
values in Table 2, the average mass error for these N-glycans
was 38.7 ppm (from calculated sodiated masses). The prox-
imity of the AWM [M+Na]+ values to their calculated values
indicated that the automated sample preparation was suffi-
ciently homogeneous across multiple analysis regions so as
to minimize mass deviations caused by matrix heterogeneity.
It should be noted that external calibration on an adjacent
tissue is not ideal for precious tissues. As such, internal
calibrants or a higher mass accuracy MS instrument would
constitute important additions to any future N-glycan MALDI
imaging workflow [18, 19].
Figure 4g–i provides the log ion intensity maps of AWM
[M+Na]+: 2304.909 for the two PNGase F-treated sections
and buffer control section, respectively. As this example ion
intensity map shows, the spatial distribution of N-glycans, in
this case to the cortex, can be clearly visualized using this
MALDI imaging method. Figure S6 in the ESM presents the
remaining ion intensity maps which were above the DIPPS
cut-off threshold for one of the PNGase F-treated replicate
kidney sections.
In order to demonstrate data-dependent visualization of
histological regions within the kidney tissue, the full data set
was loaded into the SCiLS software platform and processed
for both spatial segmentation analysis [28] and pLSA [29].
First, the MALDI imaging data was preprocessed and seg-
mented. Figure 5a shows the result of this spatial segmenta-
tion. The levels selected in the segmentation dendogram
allowed delineation of the cortex and medulla/pelvic regions
of the kidney while also separating the PNGase F-treated and
buffer control regions. To address the same question in a
different manner, random initialization pLSAwith 10 compo-
nents was applied to the same data set. Figure 5b–d presents
three histologically relevant components from this analysis,
which overlay with the medulla/pelvis (Fig. 5b) as well as the
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cortex (Fig. 5c, d) of the kidney sections analyzed. Figure 5e–
h shows the ion intensity maps for four individual [M+Na]+
values which correspond to (Hex)2 (HexNAc)2 +
(Man)3(GlcNAc)2 (m/z 1663.632, Fig. 5e), (Hex)6 +
(M a n ) 3 ( G l cNA c ) 2 (m / z 1 9 0 5 . 6 9 7 , F i g . 5 f ) ,
(Hex)2(HexNAc)3(Deoxyhexose)3 + (Man)3(GlcNAc)2 (m/z
2304.909, Fig. 5g), and (Hex)3(HexNAc)4 (Deoxyhexose)4 +
(Man)3(GlcNAc)2 (m/z 2816.115, Fig. 5h). A consistent, spa-
tially distributed signal was present for all four of these N-
glycans across the kidney tissue.
With respect to tissue specificity, the four N-glycans listed
above localized to the medulla/pelvis (Fig. 5e) and cortex
(Fig. 5f–h). As expected, no normalized intensity was visible
in the buffer control region. Importantly, the observation of
duplicate reproducibility and the ability to clearly annotate
histologically relevant spatial distributions forN-glycans dem-
onstrate the utility of the presented method for molecular
imaging.
To further improve the results presented here and detect
more of the LC-MS/MS-identified N-glycans by MALDI
imaging, several strategies could augment the presented meth-
od. Firstly, additional steps which promote protein denatur-
ation (e.g., reduction/alkylation) could be employed to im-
prove PNGase F enzyme efficiency [17]. Predigestion deriv-
atization steps could also be employed to allow routine detec-
tion of sialylated N-glycans in MALDI imaging [30]. These
kinds of predigestion treatments are very suitable for FFPE
tissues, as the proteome is immobilized by cross-links, and as
such, tissue sections can be completely immersed in reagent
solutions without risking analyte delocalization and loss of
Fig. 4 MALDI imagingMS ofN-linked glycans released from formalin-
fixed murine kidney sections. Formalin-fixed murine kidney sections
were treated with citric acid antigen retrieval prior to printing of 30 nL/
spot dialyzed PNGase F or buffer control arrays with 250 μm spacing
onto the tissue. 2,5-DHB (20 mg/mL) was sprayed onto the tissue
sections, and MS spectra were acquired by oversampling at 100 μm
intervals using a MALDI-TOF/TOF MS instrument. Hematoxylin and
eosin stained tissue sections are shown for PNGase F-treated (a, b) and
buffer control-treated (c) regions, respectively. d–fDIPPS maps of the 13
m/z values with the highest DIPPS score (i.e., highest proportion in
PNGase F-treated regions as compared to control) for the PNGase F (d,
e) and buffer control (f) regions, respectively. g–i The log ion intensity
maps for one of these 13 m/z values, in this case 2304.909, for the
PNGase F (g, h) and buffer control (i) regions. Both DIPPS maps and
log ion intensity maps show increased counts/intensity in the cortex of the
kidney
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Fig. 5 MALDI imagingMS ofN-linked glycans released from formalin-
fixed murine kidney sections. Formalin-fixed murine kidney sections
were treated with antigen retrieval prior to printing of 30 nL/spot dialyzed
PNGase F or buffer control arrays with 250 μm spacing. 2,5-DHB
(20 mg/mL) was sprayed onto the sections and MS spectra were acquired
by oversampling at 100 μm intervals using a MALDI-TOF/TOF MS
instrument. Data was loaded raw into SCiLS, preprocessed for baseline
subtraction and normalization to total ion current (TIC) prior to segmen-
tation analysis (maximum processing mode, interval width of 0.5 Da,
strong smoothing) and pLSA (10 component, interval width of 0.5 Da,
random initiation). Regions are outlined for PNGase F regions 1 (red) and
2 (blue), as well as control (green) and calibrant (small red box) regions. a
The segmentation map for the entire data set, which discriminates be-
tween the cortex and medulla/pelvis of the kidney at the segmentation
levels selected (see inset). b–d Components 1, 2, and 8 from the pLSA
analysis, which also discriminate the same regions of the tissue. e–h Ion
intensity maps for (Hex)2 (HexNAc)2 + (Man)3(GlcNAc)2 (m/z
1663.632) , (Hex)6 + (Man)3(GlcNAc)2 (m /z 1905.697) ,
(Hex)2(HexNAc)3(Deoxyhexose)3 + (Man)3(GlcNAc)2 (m/z 2304.909),
and (Hex)3(HexNAc)4 (Deoxyhexose)4 + (Man)3(GlcNAc)2 (m/z
2816.115). Intensity scales are autocorrected for these intensity maps
(with weak denoising) and scale bars are included
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spatial information. In addition to signal improvement, the
glycan standard created for this study could be implemented
as an internal calibrant to improve mass accuracy even further
and improve confidence in correlations between MALDI im-
aging and LC-MS/MS. [19] Finally, N-glycan analysis in
MALDI imaging could also be attempted in the negative
mode. Although the ionization intensity might be lower than
positive mode, valuable MS/MS fragmentation data could be
acquired similar to that observed in the LS-ESI-MS/MS anal-
ysis. Additionally, negative mode analysis of native N-glycan
anion adducts [31–33] can be well characterized by MALDI.
However, work from the same author shows that derivatiza-
tion of sialic acids can also be used to detect and to distinguish
between α 2-3 and α 2-6 linkages in MALDI [30].
The sum of the presented data indicates that the methods
developed in this study allow for spatial annotation of N-
glycans on FFPE tissue sections as well as straightforward
in-solution N-glycan release for downstream characterization
by LC-MS/MS. The use of automated sample preparation
instruments for PNGase F printing and matrix spraying pre-
sents a clear advantage over previous methods [17].
In the context of the work published during the preparation
of the current manuscript, Powers et al. also presentedN-glycan
MALDI imaging data for murine kidney [18]. This work
matched 28 N-glycan values from murine kidney to those
available from the Consortium for Functional Glycomics
(CFG) [18]. The method presented here is advantageous as it
implements commercially available PNGase F rather than
expressed and purified enzyme used previously [18]. This
makes the method more accessible to MALDI imaging groups.
Furthermore, 14 of the previously detected N-glycan masses
were characterized by LC-MS/MS and matching candidate
masses were detected for 23 of the 28 N-glycans [18]. The
work presented here therefore presents a comprehensive
MALDI imaging and glycomic characterization of N-glycans
which complements a previous work on kidney tissue.
As mentioned above, further method development will
aim to improve the sensitivity and mass accuracy for N-
glycan MALDI imaging. Ultimately, the methods present-
ed will be applied to N-glycan profiling in human cancer
tissues [18]. Ovarian cancer would benefit from the appli-
cation of the methods developed here for two reasons:
firstly, the inadequate specificity of the glycoprotein
CA125 as a biomarker for early stage diagnosis [34] and,
secondly, extensive reporting of altered glycan patterns for
this disease. For example, glycan alterations have been
detected in the serum of patients with advanced ovarian
cancer, including increased levels of sialyl Lewis x (sLeX)
and core-fucosylation of agalactosylated biantennary gly-
cans (FA2) [35].
Future analyses employing N-glycan MALDI imaging will
initially focus solely on the identification of tissue regions
(e.g., stage I versus stage III ovarian tumors) where the
number and/or type of detectable N-glycan species changes.
The identification of these tissue regions will allow one of
several additional experimental lines to be pursued. Firstly, the
N-glycan profiles can be used to develop tissue-specific clas-
sifiers in a similar fashion to those developed for proteomic
MALDI imaging profiles [14]. Secondly, the profiles could be
used to guide glycoproteomics analyses where tryptic peptides
are extracted, glycopeptides are enriched, and the mixture is
analyzed by LC-MS/MS. Finally, further strategies could be
developed which allow direct MALDI imaging of glycopep-
tides in a complex mixture of tryptic peptides, either through
derivatization [36] or spatially sensitive enrichment. The
straightforward methods presented here will allow the direct
glycomic analysis of N-glycans in the vast archives of human
cancer tissue which are available globally and ultimately
increase our understanding of cancer biology through large
retrospective studies.
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